| Budget Amount *help |
¥2,730,000 (Direct Cost: ¥2,100,000、Indirect Cost: ¥630,000)
Fiscal Year 2014: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2013: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
Breast cancer has poor survival and high recurrence rates for aggressive metastatic disease. There is no preferred agent for metastasis of breast cancer. In this study, I show that aryl hydrocarbon receptor (AhR) ligand, YL-109 has ability to inhibit breast cancer cell growth and invasiveness in vitro and in vivo. YL-109 increased the expression of carboxyl terminus of Hsp70-interacting protein (CHIP), which suppresses tumorigenic and metastatic potential of breast cancer cells. YL-109 induced CHIP transcription because of the recruitment of the AhR to upstream of CHIP gene in breast cancer cells. Consistently, the antitumor effects of YL-109 were depressed by CHIP or AhR knockdown in breast cancer cells. Taken together, my findings indicate that a novel agent YL-109 inhibits cell growth and metastatic potential by inducing CHIP expression through AhR signaling in breast cancer cells. It suggests that YL-109 is a potential candidate for breast cancer therapy.
|
